SLEB16 is a rare autosomal-recessive form of Systemic Lupus Erythematosus (SLE). It is a chronic, multi-system, auto-immune disorder characterized by the production of antibodies against the patient’s own nuclear antigens. Symptoms can range from fever, joint pain, malar rashes, photosensitivity and fatigue to more serious complications such as arthritis, pleuritis, pericarditis, renal failure, seizures and psychosis. The disorder usually develops in childhood. While other forms of SLE has been found to be more prevalent among females, no such gender bias has been seen in this autosomal-recessive form.
Diagnosis of the disorder is made based on criteria established by the American College of Rheumatology (ACR). The most important of these criteria is the presence of antinuclear antibodies. Laboratory investigations may also include tests to determine erythrocyte sedimentation rates (ESR) as well as anti-DNA, anti-Sm, anti-RNP, anti-Ro and anti‑La antibodies. While there is currently no cure for SLE, certain medications can help control the disease and prevent flare-ups. These include non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants and antimalarial drugs like hydroxychloroquine. Patients are also advised to limit sun exposure and maintain a healthy lifestyle.